Spring 2024 LipidSpin Articles | National Lipid Association Online

Daniel E. Soffer, MD, FNLA*	From the NLA President: Charging Ahead Hello fellow lipid lovers! I hope everyone had a wonderful holiday season and is looking forward to a productive and prosperous 2024. The new year brings many exciting new initiatives and projects over the coming months, including but not limited to: SIX new NLA manuscripts are in the pipeline and will be published by summer of 2024. Annual Scientific Sessions will be held at Caesars Palace in Las Vegas, Nevada, May 30 - June 2, 2024. You won’t want to miss this... more
Kaye-Eileen Willard, MD, FNLA*	Editor's Corner: Care "In the Trenches," Anything but Monochromatic or Simple As always, LipidSpin is a labor of love – to collaborate on a selection of contributions that we, as Lipid Specialists within the NLA, see as critically important topics for in depth review and dissemination. The process by which each of these journal editions evolve is well-oiled through years of practice and refinement but done with explosive creativity each time. As the editor, it is always a joy to see how an initial theme, which is selected by the presidents of the... more
Chima Nwizu, MD, FAAFP, FNLA*	From the SWLA President: Taking a Closer Look for Greater Care Outcomes I am honored as the Southwest Lipid Association President, in collaboration with the President of the Pacific Lipid Association, to bring you the first LipidSpin edition of 2024. I enthusiastically share these articles with the membership of the NLA, knowing the significant impact we as Lipid Specialists collectively make to enhance preventive cardiometabolic care. This importance is underscored by the fact that cardiovascular disease remains the number one killer of our fellow... more
Geeta Sikand, MA, RDN, FAND, CLS, FNLA*	Letter from the PLA President: Small Discoveries Make Big Victories Lipid Management in Specific Populations, the theme for this edition of LipidSpin, is a culmination of what Dr. Chima Nwizu, SWLA President, and I believe moves our organization forward. The National Lipid Association realizes the importance of understanding, investigating, and advocating treatment options for a variety of conditions; including those that afflict a limited population. Every article section in this edition may not apply to all your patients, but for the specific... more
Shubham Agarwal, MD Michael Madueke Keith C. Ferdinand, MD, FNLA* Juliana Savic, MD Wenjun Fan, MD, PhD Zahid Ahmad, MD, FNLA*	Clinical Feature: Dyslipidemia and ASCVD in Non-White Ethnic, Racial, and Ancestral Groups Introduction While atherosclerotic cardiovascular disease (ASCVD) and dyslipidemia affect all populations, their impact is far from uniform. Many interwoven factors, including genetics, sociocultural determinants, and environmental exposures, create a diverse picture of risk across different groups. Understanding this intricate landscape is crucial for tailoring effective prevention and treatment strategies, ultimately reducing the burden of ASCVD, and promoting... more
Beth Sherry, MD Michael Garshick, MD	Guest Editorial: Lipid Management in Patients with Chronic Inflammatory Conditions Introduction Immune system activation – i.e., systemic inflammation, plays an essential role in all stages of atherosclerosis, from the development of the fatty streak to acute plaque rupture.¹ Autoimmune diseases are common, with a prevalence of up to 8% of the United States (US) adult population. Diseases such as rheumatoid arthritis (RA), psoriasis, systemic lupus erythematosus (SLE), rare conditions such as the inflammatory myopathies (IMs),... more
Nirmita Doshi, MD Safa Aldabyani, MD Aman Rajpal, MD, DABOM	EBM Tools for Practice: The Thyroid-Lipid Axis: Implications for Atherosclerosis and Beyond Dyslipidemia frequently presents in individuals with thyroid dysfunction, attributed to the influence of thyroid hormones on various key metabolic pathways, thereby contributing to an elevated cardiovascular (CV) risk.¹ In this discussion, we delve into the intricate connection between thyroid dysfunction and lipid metabolism, providing recommendations for effective surveillance and management. Overview of Thyroid Dysfunction Thyroid... more
Usman Sagheer, MD Dinesh K. Kalra, MD FACC, FSCCT, FSCMR, FNLA	Lipid Luminations: Lipid Management in Chronic Kidney Disease Introduction Chronic kidney disease (CKD) ranks among the top five causes of global mortality, affecting approximately 35.5 million people in the United States (US).^1,2 Despite being preventable and treatable, the prevalence of CKD and related mortality are on the rise, making it an important global health issue. According to the Global Burden of Disease (GBD) study, CKD is projected to become the fifth leading cause of global mortality by 2040, and the... more
Mariana L. Henry, MPH Pamela Papp, APRN, C-NP, FNLA Robert Wild MD, PhD, FNLA Eliot A. Brinton MD, FAHA, FNLA, FACE Merle Myerson MD, EdD, FACC, FNLA	Specialty Corner: Lipid Management in Pregnancy and Lactation Introduction Normal pregnancy is characterized by physiologic increases in maternal levels of cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C). These lipoproteins are taken up by the placenta and support optimal fetal development and maternal health during pregnancy.¹ Patients with pre-existing dyslipidemia or those who develop dyslipidemia during pregnancy should have an evaluation... more
Pamela L. Alebna, MD, MPH Leonid Khokhlov, MD Anurag Mehta, MD, FACC	Practical Pearls: Dyslipidemia Management in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Key points MASLD is a risk factor for atherosclerotic cardiovascular disease and is associated with cardiometabolic risk factors, such as obesity (adiposopathy), hypertension, insulin resistance, diabetes and dyslipidemia. The cornerstone of MASLD management is aggressive treatment of risk factors, lifestyle interventions, and reducing excess adiposity. Dyslipidemia occurs in approximately 60-70% of individuals with MASLD. ... more
Gabriella E. Webster, MS Amelia Vinson, RN Luke Hamilton, MS Don Wilson, MD, FNLA*	Case Study: Incident Type 2 Diabetes Mellitus following Statin Initiation in Youth Introduction The association of statin use, and incident type 2 diabetes (T2D) is well established in adults.¹ Similar observations have not been reported in youth. Despite this association, the benefits of statins in preventing atherosclerotic cardiovascular disease (ASCVD) appear to outweigh their adverse effects on glycemic control. Case #1 A 14-year-old White, non-Hispanic male was referred for fasting triglycerides (TG... more
Anandita Kulkarni, MD, FACC	SWLA Chapter Update: Robust Participation There has been robust participation among SWLA members in the National Lipid Association activities and outstanding contributions to the field of lipidology! Here are just a few highlights of what our productive group achieved in 2023! Planned by SWLA leadership, Christie Ballantyne, MD; Nicole Ciffone, ANP-C; Lauren Willians, RD; and Chima Nwizu, MD, the 2023 Fall Clinical Update held in Scottsdale, AZ, was a successful meeting and brought together many lipid enthusiasts from around... more
Michael Wilkinson, MD, FACC, FNLA*	PLA Chapter Update: Growth in Our Community It is an honor to contribute this PLA Chapter Update to the current edition of LipidSpin. Congratulations to all PLA and SWLA authors who contributed to this edition. We sincerely appreciate the time and effort involved, and we are also grateful for the mentorship provided by senior authors to individuals who may be newer to the field of clinical lipidology. LipidSpin is such a critical part of the NLA’s efforts to help educate and generate excitement around the field of lipidology! ... more
National Lipid Association	In Memoriam: David Capuzzi, MD, PhD, FNLA Founding Member of the Northeast Lipid Association A physician’s physician A true patient advocate Mentor Friend David Capuzzi, MD, PhD, FNLA, member of the National Lipid Association since 2004, leader in the Northeast Lipid Association, colleague to many, and friend passed away on February 15, 2024 at the age of 85.... more